|
US 12,319,675 B2 |
|
| Chromene derivatives as inhibitors of TCR-Nck interaction |
| Julio Castro, Barcelona (ES); Andrés Gagete Mateos, Valencia (ES); Peter J. Machin, London (GB); and Christopher Loren Vandeusen, Hopkinton, MA (US) |
| Assigned to Artax Biopharma Inc., Cambridge, MA (US) |
| Filed by Artax Biopharma Inc., Cambridge, MA (US) |
| Filed on Sep. 21, 2023, as Appl. No. 18/471,594. |
| Application 18/471,594 is a continuation of application No. 17/240,041, filed on Apr. 26, 2021, granted, now 11,807,633. |
| Application 17/240,041 is a continuation of application No. 16/878,842, filed on May 20, 2020, granted, now 11,008,310, issued on May 18, 2021. |
| Application 16/878,842 is a continuation of application No. 16/287,771, filed on Feb. 27, 2019, granted, now 10,696,663, issued on Jun. 30, 2020. |
| Claims priority of provisional application 62/635,834, filed on Feb. 27, 2018. |
| Prior Publication US 2024/0199592 A1, Jun. 20, 2024 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. C07D 413/06 (2006.01); A61P 3/10 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01); C07D 311/22 (2006.01); C07D 311/58 (2006.01); C07D 405/06 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01) |
